Relapsing Forms of Multiple Sclerosis Clinical Trial
— FUSIONOfficial title:
A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis
The primary objectives are to investigate the safety and tolerability of BIIB091 monotherapy in participants with relapsing multiple sclerosis (RMS) (Part 1), and to evaluate the effects of BIIB091 combination therapy with Diroximel Fumarate (DRF) compared with the DRF monotherapy arm, on the key Magnetic Resonance Imaging (MRI) measure of active Central Nervous System (CNS) inflammation (Part 2). The secondary objectives are to evaluate the effects of BIIB091 monotherapy on the MRI measures of active CNS inflammation, to evaluate the effects of BIIB091 combination therapy with DRF compared with the DRF monotherapy arm on additional MRI measures of active CNS inflammation, to investigate the safety and tolerability of BIIB091 combination therapy with DRF in participants with RMS.
Status | Recruiting |
Enrollment | 275 |
Est. completion date | November 9, 2026 |
Est. primary completion date | July 10, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Key Inclusion Criteria: 1. Diagnosis of RMS [relapsing-remitting multiple sclerosis (RRMS) or active secondary progressive multiple sclerosis (SPMS)] in accordance with the 2017 Revised McDonald criteria. 2. Time since MS symptom onset is <20 years. 3. Must have expanded disability status scale (EDSS) score of 0 through 5.0 at screening and baseline. 4. Must have at least 1 of the following occurring prior to Baseline (Day 1): - =2 clinical relapses in the last 24 months (but not within 30 days prior to Baseline [Day 1]) with at least 1 relapse during the last 12 months prior to randomization. - =1 clinical relapse within the past 24 months (but not within 30 days prior to Baseline [Day 1]) and =1 new brain MRI lesion (Gd-positive and/or new or enlarging T2 hyperintense lesion) within the past 12 months prior to randomization. The screening MRI could be used to satisfy this criterion (if needed for inclusion, local reading is required). For new or enlarging T2 hyperintense lesions, the reference scan cannot be >12 months prior to randomization. - =1 GdE lesion on brain MRI within 6 months prior to randomization. Key Exclusion Criteria: 1. Diagnosis of primary progressive multiple sclerosis (PPMS) in accordance with the 2017 Revised McDonald criteria. 2. An MS relapse that has occurred within 30 days prior to Baseline (Day 1) or the participant has not stabilized from a previous relapse at the time of screening. 3. History of severe allergic, anaphylactic reactions or hypersensitivity reaction to BIIB091 or DRF, the excipients contained in the formulation, and if appropriate, any diagnostic agents to be administered during the study, including the following: - Known hypersensitivity to any components of the study treatment - Known hypersensitivity to previous fumarate or bruton's tyrosine kinase (BTK) inhibitor treatments - History of hypersensitivity to parenteral administration of Gd-based contrast agents 4. Evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within the past 4 weeks prior to Baseline. 5. History or positive test result at screening for human immunodeficiency virus (HIV). 6. Current or history of hepatitis C infection regardless of viral load. 7. Current or possible hepatitis B. 8. Current enrollment or plan to enroll in any other drug, biological, device, clinical study, or treatment with an investigational drug or approved therapy for investigational use within 90 days prior to randomization or 5 half-lives of the drug or therapy, whichever is longer. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply. |
Country | Name | City | State |
---|---|---|---|
Bulgaria | 'MHAT Avis - Medica' OOD | Pleven | |
Bulgaria | UMHAT 'Dr. Georgi Stranski', EAD | Pleven | |
Bulgaria | UMHAT 'Sv. Georgi', EAD | Plovdiv | |
Bulgaria | Acibadem City Clinic Tokuda University Hospital Ead | Sofia | |
Bulgaria | DCC Neoclinic EAD | Sofia | |
Bulgaria | Diagnostic Consultation Center CONVEX EOOD | Sofia | |
Bulgaria | MHATNP 'Sv.Naum', EAD | Sofia | |
Bulgaria | UMHAT "Sv. Ivan Rilski", EAD | Sofia | |
Bulgaria | University First MHAT-Sofia, 'St. Joan Krastitel' EAD | Sofia | |
Czechia | Fakultni nemocnice u sv. Anny v Brne | Brno | |
Czechia | Fakultni nemocnice Hradec Kralove | Hradec Kralove | |
Czechia | Nemocnice Jihlava p.o. | Jihlava | |
Czechia | Fakultni Thomayerova nemocnice | Praha 4-Krc | |
Czechia | Krajska zdravotni a.s. - Nemocnice Teplice o.z. | Teplice | |
Germany | Klinikum Bayreuth GmbH- Hohe Warte | Bayreuth | Bayern |
Germany | Studienzentrum fur Neurologie und Psychiatrie | Boeblingen | Baden Wuerttemberg |
Germany | Universitaetsklinikum Carl Gustav Carus TU Dresden | Dresden | |
Germany | Universitaetsklinikum Duesseldorf AoeR | Duesseldorf | Nordrhein Westfalen |
Germany | ZNS - Zentrum fuer Neurologisch-Psychiatrische Studien | Siegen | Nordrhein Westfalen |
Germany | Neuropraxis Muenchen Sued | Unterhaching | Bayern |
Italy | Fondazione Istituto G.Giglio di Cefalù | Cefalù | Palermo |
Italy | IRCCS Ospedale Policlinico San Martino | Genova | |
Italy | Azienda Ospedaliera Universitaria- Università degli Studi della Campania "Luigi Vanvitelli" | Napoli | |
Italy | Fondazione Istituto Neurologico Casimiro Mondino | Pavia | |
Italy | I.R.C.C.S. Neuromed-Istituto Neurologico Mediterraneo | Pozzilli | Isernia |
Italy | Azienda Ospedaliera Universitaria Policlinico Tor Vergata | Roma | |
Italy | Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza | Roma | |
Poland | COPERNICUS Podmiot Leczniczy Sp. z o. o., | Gdansk | |
Poland | Samodzielny Publiczny Specjalistyczny Szpital Zachodni im. Jana Pawla II | Grodzisk Mazowiecki | |
Poland | Centrum Medyczne Pratia Katowice | Katowice | |
Poland | M.A. - LEK A.M.Maciejowscy SC. | Katowice | |
Poland | Nzoz Novo-Med | Katowice | |
Poland | Resmedica Sp.z o.o | Kielce | |
Poland | MCD Medical | Krakow | |
Poland | Szpital Uniwersytecki w Krakowie | Krakow | |
Poland | Centrum Neurologii K. Selmaj | Lodz | |
Poland | Instytut Zdrowia dr Boczarska-Jedynak sp.z.o.o, Sp.K | Oswiecim | |
Poland | Med-Polonia Sp. z o.o. | Poznan | |
Poland | NZOZ 'NEURO-KARD', 'Ilkowski i Partnerzy' Sp. Partn. Lek. | Poznan | |
Poland | Nzoz Palomed | Rzeszów | |
Poland | NeuroProtect Sp. z o.o. | Warszawa | |
Poland | Wielospecjalistyczne Centrum Medyczne Ibismed | Zabrze | |
Puerto Rico | Caribbean Center for Clinical Research | Guaynabo | |
Romania | S.C Neurocity S.R.L | Bucure?ti | |
Romania | Spitalul Universitar de Urgenta Elias | Bucuresti | |
Romania | S.C Clubul Sanatatii SRL | Campulung Muscel | |
Spain | Hospital del Mar | Barcelona | |
Spain | Hospital Universitario Reina Sofia | Cordoba | |
Spain | Hospital Universitario Virgen de la Arrixaca | El Palmar | Murcia |
Spain | Hospital Universitario Ramon y Cajal | Madrid | |
Spain | Hospital Regional Universitario de Malaga | Malaga | |
Spain | Hospital Universitario Quironsalud Madrid | Pozuelo de Alarcon | Madrid |
Switzerland | Inselspital - Universitaetsspital Bern | Bern | |
Switzerland | Ospedale Regionale di Lugano | Lugano | Ticino |
Switzerland | Universitaetsspital Zuerich | Zuerich | |
United States | University of New Mexico | Albuquerque | New Mexico |
United States | University of Colorado School of Medic | Aurora | Colorado |
United States | Alta Bates Summit Medical Center | Berkeley | California |
United States | The Cleveland Clinic Foundation | Cleveland | Ohio |
United States | The Boster Center for Multiple Sclerosis | Columbus | Ohio |
United States | Neurology Clinic, PC | Cordova | Tennessee |
United States | Fort Wayne Neurological Center | Fort Wayne | Indiana |
United States | University of Kansas Medical Center Research Institute, Inc. | Kansas City | Kansas |
United States | International Neurorehabilitation Institute | Lutherville | Maryland |
United States | University of Wisconsin Hospital and Clinics | Madison | Wisconsin |
United States | University of California at Irvine Medical Center | Orange | California |
United States | South Shore Neurologic Associates, P.C. | Patchogue | New York |
United States | Washington University | Saint Louis | Missouri |
United States | The University of Texas Health Science Center San Antonio | San Antonio | Texas |
United States | HonorHealth Neurology | Scottsdale | Arizona |
United States | University of South Florida | Tampa | Florida |
United States | Holy Name | Teaneck | New Jersey |
United States | Vero Beach Neurology and Research Institute | Vero Beach | Florida |
United States | Wake Forest University - School of Medicine - Central | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Biogen |
United States, Bulgaria, Czechia, Germany, Italy, Poland, Puerto Rico, Romania, Spain, Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Part 1: Number of Participants With Adverse Events (AEs) | An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product or auxiliary medicinal product, whether or not related to the medicinal (investigational) product or auxiliary medicinal product. | Day 1 up to Week 50 | |
Primary | Part 1: Number of Participants With Serious Adverse Events (SAEs) | SAE is any untoward medical occurrence that at any dose results in death, in the view of the investigator, places the participant at immediate risk of death (a life-threatening event), requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect or is a medically important event. | From signing the informed consent form (ICF) to Week 50 | |
Primary | Part 2: Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions | Week 8 to Week 16 | ||
Secondary | Part 1: Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions | Week 8 to Week 16 | ||
Secondary | Part 1: Cumulative Number of New or Enlarging T2 Hyperintense Lesions | Week 8 to Week 16 | ||
Secondary | Part 1: Cumulative Volume of New or Enlarging T2 Hyperintense Lesions | Week 8 to Week 16 | ||
Secondary | Part 1: Mean Change From Baseline in QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF), RR, PR, QRS, and QT Intervals | Up to Week 50 | ||
Secondary | Part 1: Number of Participants With Change From Baseline in Heart Rate | Up to Week 50 | ||
Secondary | Part 1: Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities | Up to Week 50 | ||
Secondary | Part 2: Cumulative Number of New or Enlarging T2 Hyperintense Lesions | Week 8 to Week 16 | ||
Secondary | Part 2: Cumulative Volume of New or Enlarging T2 Hyperintense Lesions | Week 8 to Week 16 | ||
Secondary | Part 2: Number of Participants With AEs | An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product or auxiliary medicinal product, whether or not related to the medicinal (investigational) product or auxiliary medicinal product. | Day 1 up to Week 50 | |
Secondary | Part 2: Number of Participants With SAEs | SAE is any untoward medical occurrence that at any dose results in death, in the view of the investigator, places the participant at immediate risk of death (a life-threatening event), requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect or is a medically important event. | From signing of ICF up to Week 50 | |
Secondary | Part 2: Number of Participants With Change From Baseline in QTcF, RR, PR, QRS, and QT intervals | Up to Week 50 | ||
Secondary | Part 2: Number of Participants With Change From Baseline in Heart Rate | Up to Week 50 | ||
Secondary | Part 2: Number of Participants With ECG Abnormalities as Assessed by 12-Lead ECG Measurements | Up to Week 50 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01201356 -
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis
|
Phase 3 | |
Suspended |
NCT04909502 -
Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis
|
Phase 2 | |
Recruiting |
NCT05083923 -
A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)
|
Phase 3 | |
Completed |
NCT02230969 -
Plegridy Observational Program
|
||
Withdrawn |
NCT02428218 -
Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
|
Phase 3 | |
Completed |
NCT01873417 -
Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States
|
Phase 4 | |
Completed |
NCT04676555 -
Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis
|
||
Completed |
NCT00424788 -
A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
|
Phase 0 | |
Recruiting |
NCT06251986 -
A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice
|
||
Completed |
NCT02097849 -
Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
|
Phase 2 | |
Completed |
NCT01903291 -
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
|
N/A | |
Completed |
NCT01216072 -
A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis
|
Phase 4 |